MA43596A1 - New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancers - Google Patents
New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancersInfo
- Publication number
- MA43596A1 MA43596A1 MA43596A MA43596A MA43596A1 MA 43596 A1 MA43596 A1 MA 43596A1 MA 43596 A MA43596 A MA 43596A MA 43596 A MA43596 A MA 43596A MA 43596 A1 MA43596 A1 MA 43596A1
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- relates
- present
- immunotherapy
- cancers
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 title 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 title 1
- 201000004101 esophageal cancer Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne des peptides, des protéines, des acides nucléiques et des cellules à utiliser dans des procédés immunothérapeutiques. La présente invention porte en particulier sur l'immunothérapie du cancer. La présente invention a également trait à des épitopes peptidiques de lymphocytes t associés à une tumeur, seuls ou combinés à d'autres peptides associés à une tumeur, qui peuvent par exemple servir en tant que principes actifs pharmaceutiques de compositions vaccinales qui stimulent des réponses immunitaires antitumorales, ou stimuler des lymphocytes t ex vivo afin de les transférer ensuite dans des patients. Des peptides liés aux molécules du complexe majeur d'histocompatibilité (cmh), ou des peptides en tant que tels, peuvent également être les cibles d'anticorps, de récepteurs de lymphocytes t solubles et d'autres molécules de liaison.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. The present invention relates in particular to cancer immunotherapy. The present invention also relates to peptide epitopes of tumor associated t cells, alone or in combination with other tumor associated peptides, which can for example serve as pharmaceutical active ingredients in vaccine compositions which stimulate immune responses. antitumor, or stimulate ex vivo T lymphocytes in order to transfer them to patients. Peptides bound to major histocompatibility complex (cmh) molecules, or peptides as such, can also be the targets of antibodies, soluble T cell receptors and other binding molecules.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA43596A MA43596A1 (en) | 2018-10-26 | 2018-10-26 | New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancers |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MA43596A MA43596A1 (en) | 2018-10-26 | 2018-10-26 | New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43596A1 true MA43596A1 (en) | 2021-04-30 |
Family
ID=75687907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43596A MA43596A1 (en) | 2018-10-26 | 2018-10-26 | New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancers |
Country Status (1)
| Country | Link |
|---|---|
| MA (1) | MA43596A1 (en) |
-
2018
- 2018-10-26 MA MA43596A patent/MA43596A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42381B1 (en) | New peptides and novel peptide combination for use in immunotherapy of esophageal cancer and other cancers | |
| MA46508A1 (en) | New cell epitopes and novel combination of cell epitopes for use in immunotherapy of myeloma and other cancers | |
| MA43090A1 (en) | Peptides, peptide combinations and cell-based drugs for immunotherapy against urinary bladder cancer and other cancers | |
| MA43490A1 (en) | New peptides and combination of peptides for use in immunotherapy against various cancers | |
| MA46647A1 (en) | New peptides and combination of peptides for use in immunotherapy of pancreatic cancer and other cancers | |
| MA43330B1 (en) | Transfected T cells and T cell receptors for use in immunotherapy against cancers | |
| MA44101B1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| MA43461B1 (en) | Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers | |
| MA43327A1 (en) | Peptides and peptide combination for use in immunotherapy against non-small cell lung cancer and other cancers | |
| MA46022B1 (en) | New peptides and peptide combination for use in immunotherapy against prostate cancer and other cancers | |
| MA42294B1 (en) | New peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| MA41520B2 (en) | New peptides and peptide combination for use in immunotherapy against ovarian cancer and other cancers | |
| MA43328A1 (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| MA43435B1 (en) | NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS (SEQ ID 25 - MRAX5-003) | |
| MA44551A1 (en) | Novel peptides and novel combination of peptides for use in immunotherapy, and methods for generating scaffolds for use against pancreatic cancer and other cancers | |
| MA42045A (en) | NEW PEPTIDES AND COMBINATIONS OF PEPTIDES AND SCAFFOLDING FORMED THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL CARCINOMA (CRC) AND OTHER CANCERS | |
| MA41237B1 (en) | New peptides and peptide combinations for use in immunotherapy against hepatocellular carcinoma (chc) and other cancers | |
| MA47367B1 (en) | NOVEL PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | |
| MA43596A1 (en) | New peptides and novel combination of peptides for use in immunotherapy of esophageal cancer and other cancers | |
| MA46503A1 (en) | New cell epitopes and novel combination of cell epitopes for use in immunotherapy of myeloma and other cancers | |
| MA41664A1 (en) | Novel peptides and novel peptide combination for use in immunotherapy, and methods for generating scaffolds for use against pancreatic cancer and other cancers | |
| EA202191411A1 (en) | IMMUNOTHERAPY OF CANCER DISEASES RESTRICTED ON B * 08 PEPTIDES AND COMBINATIONS OF PEPTIDES AND RELATED METHODS |